Industry Symposium Supported by Pfizer: A road map for integration of treatment of Relapsed and Refractory Multiple Myeloma in the community: harnessing the power of BCMA Bispecific Antibodies – A Blueprint for Academic and Community Collaboration
Chair: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
08:00 - 09:00 East Coast USA Time
Industry Symposium Supported by Pfizer: A road map for integration of treatment of Relapsed and Refractory Multiple Myeloma in the community: harnessing the power of BCMA Bispecific Antibodies – A Blueprint for Academic and Community Collaboration
Location: Hall FG
Chair: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
08:00 - 08:05 East Coast USA Time
Welcome and Introductions
Location: Hall FG
Speaker: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
08:05 - 08:20 East Coast USA Time
Bringing Innovative Therapies to the Point of Care: BCMA BsAbs in Relapsed and Refractory Multiple Myeloma
Location: Hall FG
Speaker: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
08:20 - 08:30 East Coast USA Time
Clinical Considerations on Safety When Using BCMA BsAbs
Location: Hall FG
Speaker: Albert Oriol, PhD (he/him/his) – Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain
08:30 - 08:40 East Coast USA Time
Perspectives on Community Use of BCMA BsAbs: Expanding Access to Novel Therapies
When to treat relapse: MRD positivity or symptomatic relapse?
Location: Hall FG
Speaker: Fredrik Schjesvold, MD, PhD – Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo
09:10 - 09:20 East Coast USA Time
Immunotherapy vs conventional treatment at the time of the first relapse
(PA-080) Arlocabtagene autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
Location: Room 714A
Abstract Presenter: Omar Nadeem, MD – Dana-Farber Cancer Institute
Cellular and T cell engager Immunotherapy
12:23 - 12:29 East Coast USA Time
(PA-517) BCMA CAR-T Therapy with Radiotherapy Bridging and Maintenance Achieves Unprecedented Complete Response in Extramedullary Myeloma
(PA-321) Belantamab Mafodotin plus Lenalidomide/Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma: Long-Term Efficacy and Safety Results from the Phase 1/2 BelaRd Study
Location: Room 714A
Abstract Presenter: Evangelos Terpos, MD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Myeloma Novel Drug Targets and agents
12:35 - 12:41 East Coast USA Time
(PA-199) Elevated Non-Clonal Bone Marrow Plasma Cell Fraction at Diagnosis Is Associated with Improved Outcomes in Multiple Myeloma
Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
12:53 - 12:59 East Coast USA Time
(PA-494) Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM
Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
12:59 - 13:05 East Coast USA Time
(PA-144) Whole Body Magnetic Resonance Imaging (WBMRI) for Response Evaluation in Patients with Multiple Myeloma
Location: Room 714A
Abstract Presenter: Ioannis Ntanasis-Stathopoulos, MD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Imaging, QoL and Patient-Reported Outcome and Supportive Care
12:15 - 13:15 East Coast USA Time
Lunch and Poster Session
12:15 - 13:15 East Coast USA Time
Lunch and Poster Session
Location: Hall E
13:15 - 15:05 East Coast USA Time
Plenary Session
Co-Chair: Evangelos Terpos, MD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Co-Chair: Evangelos Terpos, MD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Speaker: Adam D. Cohen, MD – Perelman School of Medicine, University of Pennsylvania
13:19 - 13:37 East Coast USA Time
(OA-16) BCMA CAR T-Cell Therapy in Newly Diagnosed Primary Plasma Cell Leukemia Ineligible for Transplantation: An Open Label, Single-arm, Phase 2 Study (CAREMM-002)
Myeloma Genomics and Microenvironment and immune profiling
14:21 - 14:25 East Coast USA Time
Abstract Introduction
Location: Hall FG
Speaker: Richard LeBlanc, MD (he/him/his) – Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, QC, Canada
14:25 - 14:43 East Coast USA Time
(OA-68) Safety and Efficacy of Linvoseltamab (LINVO) in Patients (Pts) with High-risk Smoldering Multiple Myeloma (HR-SMM): First Results from the Phase 2 LINKER-SMM1 Trial
(OA-61) A Randomized Phase 2 Study of Daratumumab, Lenalidomide, Ixazomib, and Dexamethasone in Transplant-Ineligible/Deferred Patients with Newly Diagnosed Multiple Myeloma: Alliance Foundation Trial 41
Location: Hall FG
Abstract Presenter: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)
15:15 - 16:05 East Coast USA Time
Riney Session
Co-Chair: Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School
Co-Chair: Kenneth C. Anderson, MD – Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
15:15 - 16:05 East Coast USA Time
Riney Session
Location: Hall FG
Co-Chair: Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School
Co-Chair: Kenneth C. Anderson, MD – Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
15:15 - 15:17 East Coast USA Time
Introduction
Location: Hall FG
Speaker: Nikhil Munshi, MD – Dana-Farber Cancer Institute, Harvard Medical School
Speaker: Kenneth C. Anderson, MD – Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
15:17 - 15:29 East Coast USA Time
(OA-69) The Role of Philanthropy in Accelerating the Understanding and Treatment of Multiple Myeloma
